Market Access Today’s Post

BBMCT: Start Medical Research at AIIMS Hospital BBMCT: Start Medical Research at AIIMS Hospital British Biomedicine Clinical Trials (BBMCT) has earned a reputation as a trusted partner for advanced clinical research, especially at institutions like the All India Institute of Medical Sciences (AIIMS) Hospital. As a leading center for biomedical research in India, AIIMS offers a platform for innovative studies, making it a premier site for clinical trials. BBMCT’s collaboration with AIIMS Hospital focuses on groundbreaking medical research, with the aim of advancing healthcare and improving patient outcomes. Let’s delve into why BBMCT’s partnership with AIIMS is so impactful in the field of clinical research. ## Renowned Center for Clinical Research AIIMS Hospital, a renowned institution in India, has been at the forefront of medical advancements for decades. With its reputation for providing world-class healthcare and conducting high-quality medical research, AIIMS is the ideal location for clinical trials. Collaborating with BBMCT enables access to cutting-edge technologies and methodologies, ensuring that the clinical trials conducted at AIIMS are of the highest standard. The hospital’s multidisciplinary approach and vast network of specialists facilitate diverse clinical research across various therapeutic areas, making it a go-to center for medical breakthroughs. ## Access to a Diverse Patient Base A critical component of any clinical trial is the diversity of the patient population. AIIMS Hospital, being a national healthcare hub, attracts patients from various socio-economic backgrounds, geographical locations, and with different medical conditions. This diversity provides a rich source of data, ensuring that the results from BBMCT’s clinical trials are more representative of the broader population. Whether studying chronic diseases, rare conditions, or emerging health threats, AIIMS offers an unparalleled patient pool, which plays a crucial role in the robustness and reliability of trial outcomes. ## State-of-the-Art Research Facilities Offered AIIMS Hospital is equipped with state-of-the-art research facilities, allowing BBMCT to conduct trials using the latest scientific methods and technologies. These advanced facilities include specialized laboratories, cutting-edge imaging tools, and sophisticated data management systems. From molecular research to clinical testing, the hospital’s infrastructure supports a wide range of biomedical research activities. The availability of such world-class resources enhances the quality of the clinical trials conducted at AIIMS, ensuring that results are accurate, reproducible, and innovative. ## Proficient Researchers Guarantee Dependable Results One of the key strengths of BBMCT at AIIMS Hospital is the expertise of its research team.

📑 General consent for medical research📑 New publication looking at hospital patients view on consent for medical research finds that a move toward a general consent, without limitation to specific research purposes, may better comply with patients’ wishes and maximize research potential. "Biological material and health information from patients are valuable for medical research. Under a “broad” consent model, hospital patients in Norway can consent to their biological material and health information being stored in research biobanks and used for “specific, broadly defined research purposes” within a specified medical research area but not for medical research in general. Patients are asked to provide new consent each time researchers wish to use their material in a different medical research area. This study investigated patient representatives’ views on having a general consent for medical research without limitation to specific research purposes. We also investigated preferences for the storage of biological samples, the process of consent collection, and factors motivating or hindering consent." https://lnkd.in/d_89UE6s

BBMCT: Initiate New Medical Research at AIIMS Hospital BBMCT: Initiate New Medical Research at AIIMS Hospital The world of biomedicine and clinical trials is constantly evolving, and when it comes to groundbreaking research and innovative treatments, **British Biomedicine Clinical Trials (BBMCT)** stands at the forefront. As a trusted partner for advanced clinical research at **AIIMS Hospital**, BBMCT brings cutting-edge technologies, expert management, and access to diverse patient demographics, making it an ideal choice for initiating new medical studies. This partnership focuses on advancing clinical research while maintaining the highest standards of patient care, ethical compliance, and scientific rigor. Below, we explore the core elements that make BBMCT a pivotal force in the medical research landscape. ## Cutting-Edge Research Facilities Offered BBMCT, in collaboration with **AIIMS Hospital**, offers state-of-the-art research facilities designed to meet the most stringent demands of modern clinical trials. The infrastructure at AIIMS, one of India’s premier medical institutions, is equipped with advanced laboratories, testing equipment, and specialized care units for patient monitoring. This environment ensures that all phases of clinical research, from pre-clinical testing to post-study analysis, are conducted with the highest precision and accuracy. Researchers have access to world-class resources that allow them to execute complex medical studies efficiently and safely, ensuring better outcomes for patients and more reliable data for sponsors. ## Expert Management for Clinical Studies One of the key strengths of **BBMCT** is its expert management of clinical studies. The experienced team at BBMCT oversees every aspect of a clinical trial, ensuring that each study is conducted according to the highest standards. From trial design and protocol development to patient recruitment and data collection, BBMCT’s team brings years of expertise in clinical research management. This ensures that clinical trials are streamlined, efficient, and compliant with all regulatory requirements. The team’s focus is on optimizing the trial process, minimizing delays, and maximizing the integrity of the results, which ultimately improves the reliability of the research. ## Access a Varied Patient Demographic One of the significant advantages of conducting clinical research at AIIMS Hospital through BBMCT is access to a **diverse patient population**. AIIMS is a tertiary care hospital with a large and varied patient demographic, including individuals from different regions, socioeconomic backgrounds, and ethnic groups. This diverse pool of patients enhances the generalizability of clinical trial results, ensuring that findings are relevant to a broad population.

BBMCT: Embark on New Medical Research at AIIMS hospital BBMCT: Embark on New Medical Research at AIIMS hospital British Biomedicine Clinical Trials (BBMCT) is a leading partner for advanced clinical research at AIIMS Hospital, driving medical innovation, patient care, and academic excellence. Their collaboration with AIIMS Hospital is reshaping the landscape of clinical research, addressing key gaps in medical knowledge, and bringing groundbreaking treatments to the forefront. The partnership plays a pivotal role in improving patient outcomes, accelerating the development of new medical innovations, and fostering collaboration across research teams. This blog delves into the key areas where BBMCT enhances clinical trials, creating value for patients, researchers, and the broader medical community. ### Enhances Outcomes for Patient Care One of the primary goals of clinical trials conducted by BBMCT at AIIMS Hospital is to enhance patient care. Through rigorous testing and research, clinical trials offer access to innovative treatments and therapies that are not yet widely available. These trials help identify new, more effective ways of diagnosing, treating, and managing various medical conditions, ultimately improving patient outcomes. With AIIMS’ cutting-edge facilities and BBMCT’s clinical expertise, patients benefit from early access to potentially life-saving therapies, providing them with the opportunity to participate in the development of groundbreaking medical treatments. Furthermore, clinical trials often provide patients with personalized care, focusing on tailored treatments based on the latest research findings. This contributes to more targeted, effective interventions, which enhance long-term health outcomes and overall quality of life for participants. ### Accelerates the Development of Innovations BBMCT accelerates the development of medical innovations through its partnership with AIIMS Hospital, positioning it as a leader in clinical research. Clinical trials are essential for advancing medical science, as they provide the data needed to evaluate the safety and efficacy of new drugs, therapies, or medical devices. By conducting these trials, BBMCT helps expedite the development of life-changing innovations that have the potential to revolutionize treatment protocols and improve the quality of healthcare worldwide. AIIMS, known for its world-class research capabilities, serves as the perfect partner for BBMCT to conduct advanced studies. The collaboration not only expedites the clinical trial process but also ensures that innovations undergo thorough testing to meet the highest standards before reaching the market. This rigorous testing speeds up the availability of new treatments to the broader population. ### Fosters Partnerships with Top Institutions BBMCT’s collaboration with AIIMS Hospital is just one of many strategic partnerships that help push the boundaries of medical research.

The Institute of Translational Medicine introduces itself: Our new video is online! 🧬💡 We are pleased to present our latest video, which gives deeper insights into the research projects and innovations of the Institute of Translational Medicine (ITM). It shows how ITM's mission is to overcome the infamous ‘Valley of Death’ and bridge the gap between basic research and clinical practice. The aim is to bring medical innovations and customised medical solutions to patients more quickly. 🔬🩺 🎥 In this video: - How translational medicine is overcoming the ‘Valley of Death’ - Current projects and research priorities 🔬 - The impact of new technologies on medical care 🔗 Interested? Here you go: https://bit.ly/4duDd8h #TranslationalMedicine #ITM #MedicalResearch #InnovationInHealth #FutureOfMedicine #HealthcareInnovation #BiomedicalResearch #ClinicalTrials #ResearchToPatient #MedicalBreakthroughs #TeamScience   Bernd Wollscheid Effy Vayena Catherine Jutzeler Katharina Maniura Simone Schuerle Nina Cabezas Wallscheid Viola Vogel Andrea Alimonti Shivashankar G.V. Anja Finkel Ricarda Jacomet Josefine Antonia Ammann-Tischendorf Department of Health Sciences and Technology (D-HEST), ETH Zürich ETH Zürich MAS ETH digital Clinical Research

We are very proud to belong to the 𝐈𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐞 𝐨𝐟 𝐓𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 of the Department of Health Sciences and Technology (D-HEST), ETH Zürich 🚀 📊 💻 📉 Our BMDS lab is an interdisciplinary, motivated and young research team working at the intersection of medicine, data science and biology. Our research aims to identify causes, risk factors, and biomarkers of disease progression as well as predictive factors of recovery after a neurological disease and clinical intervention. At the core of our research is a series of prospective and retrospective investigations that integrate genetic, biochemical, clinical assessments and medication history with both traditional epidemiological approaches and machine-learning algorithms. Currently, we are doing research in the fields of spinal cord injury (#SCI), #oncology, #lowerbackpain, #stroke and infectious diseases (e.g. #sepsis in children and adults). As Jörg Goldhahn mentioned in his post below: 🔗 interested in our institute? Here you go: https://lnkd.in/dK7qMv_k

Team science, cultivating patient hope, and accelerating advances in healthcare are at the heart of biomedical research. I so enjoyed writing this piece.

"Giant study finds untrustworthy trials pollute gold-standard medical reviews" 😠!!! (see https://lnkd.in/es_AgWuZ) In my first draft submission of 'The legacy of the #reproducibility crisis' to Nature Reviews Psychology (see https://lnkd.in/e2eWAgZJ), I included the following text when referring to reproducibility crisis and the prevalence of sub-par research in the broader literature: "What worries me most is how analogous this [the reproducibility crisis and unreliable studies] is to the 2008 housing market bubble where sub-prime mortgages were irresponsibly ‘re-packaged’ with better ratings to give a sense of higher quality, which eventually led to the financial crash. If ~85% of research studies are of sub-prime quality (ie not reproducible), I sincerely believe we are at risk of ‘academic rot’ spreading throughout the literature, and I dread to think of the dire consequences of an ‘academia crash’." I was asked to remove it as it was thought to be a bit 'inflammatory/hyperbolic' and beyond the scope. Well...this recent article from Nature Portfolio outlines a giant study (see https://lnkd.in/er35nfXP; NB. not yet peer-reviewed) which seems to support my analogy...that fake/flawed research is polluting the literature (being 'packaged' into systematic reviews etc). It INFURIATES me that this is the case. How can we ask the general public/society to trust our findings, if we can't even trust ourselves. It's even worse that this is happening in the medical science field - where results are literally applied to 'life & death' situations. It falls on EVERYONE in the research ecosystem to uphold and defend #ResearchIntegrity...academics, institutions, funders, publishers, policymakers...the stakes are just TOO high. #OpenScience UK Research Integrity Office (UKRIO) AAAS UK Reproducibility Network (UKRN) Marcus Munafò Dorothy Bishop Samuel Westwood, PhD Center for Open Science Health Research Authority Medicines and Healthcare products Regulatory Agency FDA

BBMCT: Commence Medical Research at AIIMS Hospital BBMCT: Commence Medical Research at AIIMS Hospital # British Biomedicine Clinical Trials (BBMCT): Your Trusted Partner for Advanced Clinical Research at AIIMS Hospital Clinical trials are a cornerstone of medical research, helping to shape the future of healthcare. In this regard, **British Biomedicine Clinical Trials (BBMCT)** has emerged as a trusted partner in advancing clinical research at **AIIMS Hospital**, one of India’s leading medical institutions. By providing access to cutting-edge research facilities, diverse patient populations, and a team of experienced professionals, BBMCT is helping transform the landscape of clinical research, ensuring new therapies and treatments are thoroughly tested and validated. ## 1. **Renowned Institution for Clinical Excellence** AIIMS Hospital, recognized globally for its clinical excellence, plays a pivotal role in advancing medical science and patient care. As a partner of BBMCT, AIIMS provides a unique environment for conducting advanced clinical trials. The hospital’s rich legacy of providing exceptional healthcare services, combined with its state-of-the-art infrastructure, enhances the quality of clinical trials undertaken at its premises. This collaboration ensures that all trials adhere to the highest standards, promoting global confidence in the results produced. ### Why Choose AIIMS for Clinical Trials? AIIMS is not just a healthcare provider but also a leader in medical research. With decades of experience and a history of groundbreaking discoveries, the hospital is home to some of the best researchers and healthcare professionals in India. Partnering with BBMCT ensures that clinical trials are conducted in an environment of clinical excellence, ensuring that results are reliable, reproducible, and ethical. ## 2. **Access to Diverse Patient Populations** One of the most significant advantages of conducting clinical trials at AIIMS Hospital with BBMCT is the access to a diverse and extensive patient population. The hospital sees patients from various socio-economic backgrounds, regions, and age groups, providing invaluable data for trials that need a broad and representative sample. ### Diverse Demographics: A Key to Robust Research Diversity in clinical trial participants is essential for testing the safety and efficacy of treatments across different population segments. BBMCT’s collaboration with AIIMS ensures that trials include a wide range of patient profiles, improving the generalizability of the research findings. The ability to access multiple patient demographics, including those with rare diseases or conditions, adds immense value to the research. ## 3. **State-of-the-Art Research Facilities Available** AIIMS Hospital boasts some of the most advanced research facilities in India, which are critical for the successful execution of clinical trials.